Duplicate blood samples were analyzed in-house (Quanterix SRX analyzer), blinded to all clinical and demographic data, using single molecule array (Simoa) technology for p-tau181 (Quanterix Advantage v2 kit), GFAP, and NfL (Quanterix Neurology 2-Plex B). Our group previously reported separate plasma NfL data in a smaller sample of the 1FLADRC.19 (link) NfL data are reported here in a larger cohort with different study aims and using a different Quanterix Simoa assay. Samples with coefficients of variation >20% were excluded (p-tau181: 10.8% of sample, GFAP: 7.4%, NfL: 6.3%). Additional sample collection and processing details are provided in Supplementary Methods.
Free full text: Click here